Over the past decade, TechnoPhage has created 3 unique scientific platforms: TechnoPhage (TP), TechnoAntibodies (TA), TechnoZeb (TZ) serving as the Group’s ‘one-of-a-kind’ backbone and strategic advantage in the development of new products.
TechnoPhage platform – Bacteriophages
TechnoPhage has developed its TechnoPhage (TP) platform, based on the unique properties of bacteriophages, which can specifically recognize, infect and kill most bacteria, including those resistant to antibiotics.
Bacteriophage preparations have relevant advantages over antibiotic therapy and can be used as therapeutics to prevent or control infections.
The emergence of pathogenic bacteria resistant to most, if not all, currently available antimicrobial agents has become a critical problem in modern medicine and the development of alternative antibacterial therapies has become one of the highest priorities.
It has been well established that bacteriophage therapy can be an innovative treatment for infections caused by multidrug resistant bacteria, including the pan-drug-resistant ones. The antibacterial effects of phages are more manageable than those of antibiotics as a consequence of their high specificity, compared to the latter.
Bacteriophage therapy using lytic bacteriophages are an efficient topical antimicrobial therapy agent in selected clinical environments because of their specificity and efficiency in lysing pathogenic bacteria, including those associated with multidrug resistance (antibiotic resistance).
Bacteriophages are not pathogenic in animals or humans, and they effectively eliminate bacteria in biofilms.
Bacteriophages are generally considered safe by the scientific community and regulatory entities, based on different theoretical considerations and experimental evidence.
Bacteriophages were discovered in the first half of the last century; following the emergence of antibiotics, resistance levels toward antibiotics have increased which have paved way for bacteriophages as a significant alternative anti-bacterial solution.
TechnoAntibodies platform – Small Domain Antibodies
TechnoAntibodies thrives in the discovery and development of recombinant single domain antibody fragments (sdAbs) against specific targets in several human diseases. SdAbs correspond to the variable regions of either the heavy (VH) or light (VL) chains of antibodies, are small in size and highly stable – the structure of sdAbs enables them to engage therapeutic targets that are inaccessible to conventional antibodies.
In addition, TechnoPhage has developed CellectAB, a complete platform of antibody discovery that uses engineered human T-cells to simultaneously perform antibody diversification into CDR regions using a unique technology of randomisation, cellular expression and discovery of binding and neutralising mAbs against recombinant targets present in the same cell.
TechnoZeb platform – Zebrafish screen
TechnoZeb was created based on an innovative approach to drug discovery by using the zebrafish as an in vivo model system for the screening of new therapeutics. The R&D strategy of TechnoZeb is designed under a fast to market rationale of drug repositioning, which is currently already recognized as an efficient and effective strategy to leverage past R&D investments from the pharmaceutical industry.
Repositioning strategy has been shown to be a promising alternative to conventional R&D for drug discovery, which is time-consuming and presents high associated costs and risks, due to unexpected adverse effects and, in many cases, efficacy below expectations. Furthermore, drug repurposing increases the success rates of market launch because the drug has already passed through a significant number of toxicology and safety assays, and, therefore, the attrition rate of pharmaceutical development becomes much reduced.